Defensin expression in human skin substitutes

Wound Repair and Regeneration

Volumn 20, Issue 3, 2012, Pages 414-424

  Gibson, Angela L ^a   Thomas Virnig, Christina L ^a,b   Centanni, John M ^b   Schlosser, Sandy J ^a   Johnston, Colette E ^b   Van Winkle, Kelly F ^b   Szilagyi, Andrea ^c   He, Li Ke ^c   Shankar, Ravi ^c   Allen Hoffmann, B Lynn ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Stratatech Corporation   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 3; GENOMIC DNA; MESSENGER RNA; BETA DEFENSIN; BETA DEFENSIN 3, HUMAN; BETA-DEFENSIN 3, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BIOENGINEERING; BURN INFECTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; INNATE IMMUNITY; KERATINOCYTE; MALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; TISSUE ENGINEERING; WOUND DRESSING; WOUND HEALING; WOUND INFECTION; ANIMAL; BURN; CELL CULTURE; DISEASE MODEL; GENE EXPRESSION; GENETICS; METABOLISM; MICROBIOLOGY; PATHOGENICITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAPHYLOCOCCAL SKIN INFECTION; WESTERN BLOTTING;

ANIMALS; BETA-DEFENSINS; BLOTTING, WESTERN; BURNS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; WOUND HEALING; WOUND INFECTION;

EID: 84860601998     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2012.00786.x     Document Type: Article

References (45)

1. Niyonsaba F, Ogawa H,. Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. J Dermatol Sci 2005; 40: 157-168. (Pubitemid 41728963)
2. Edwards R, Harding KG,. Bacteria and wound healing. Curr Opin Infect Dis 2004; 17: 91-96. (Pubitemid 38453386)
3. Bowler PG,. The 10(5) bacterial growth guideline: reassessing its clinical relevance in wound healing. Ostomy Wound Manage 2003; 49: 44-53.
4. Bennett LL, Rosenblum RS, Perlov C, Davidson JM, Barton RM, Nanney LB,. An in vivo comparison of topical agents on wound repair. Plast Reconstr Surg 2001; 108: 675-687.
5. Gibson AL, Schurr MJ, Schlosser SJ, Comer AR, Allen-Hoffmann BL,. Comparison of therapeutic antibiotic treatments on tissue-engineered human skin substitutes. Tissue Eng Part A 2008; 14: 629-638. (Pubitemid 351684735)
6. Lee SY, Kuti JL, Nicolau DP,. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005; 6: 283-295. (Pubitemid 41645594)
7. Harder J, Bartels J, Christophers E, Schroder JM,. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713.
8. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J,. Human beta-defensins. Cell Mol Life Sci 2006; 63: 1294-1313.
9. Wu Z, Hoover DM, Yang D, Boulegue C, Santamaria F, Oppenheim JJ, Lubkowski J, Lu W,. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci U S A 2003; 100: 8880-8885. (Pubitemid 36899192)
10. Jacobsen F, Baraniskin A, Mertens J, Mittler D, Mohammadi-Tabrisi A, Schubert S, Soltau M, Lehnhardt M, Behnke B, Gatermann S, Steinau HU, Steinstraesser L,. Activity of histone H1.2 in infected burn wounds. J Antimicrob Chemother 2005; 55: 735-741. (Pubitemid 40691854)
11. Jacobsen F, Mohammadi-Tabrisi A, Hirsch T, Mittler D, Mygind PH, Sonksen CP, Raventos D, Kristensen HH, Gatermann S, Lehnhardt M, Daigeler A, Steinau HU, Steinstraesser L,. Antimicrobial activity of the recombinant designer host defence peptide P-novispirin G10 in infected full-thickness wounds of porcine skin. J Antimicrob Chemother 2007; 59: 493-498. (Pubitemid 47073456)
12. Zhang L, Falla TJ,. Host defense peptides for use as potential therapeutics. Curr Opin Investig Drugs 2009; 10: 164-171.
13. Allen-Hoffmann BL, Schlosser SJ, Ivarie CA, Sattler CA, Meisner LF, O'Connor SL,. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J Invest Dermatol 2000; 114: 444-455. (Pubitemid 30415329)
14. Centanni JM, Straseski JA, Wicks A, Hank JA, Rasmussen CA, Lokuta MA, Schurr MJ, Foster KN, Faucher LD, Caruso DM, Comer AR, Allen-Hoffmann BL,. StrataGraft skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds: results from a prospective, randomized, controlled dose escalation trial. Ann Surg 2011; 254: 672-683.
15. Schurr MJ, Foster KN, Centanni JM, Comer AR, Wicks A, Gibson AL, Thomas-Virnig CL, Schlosser SJ, Faucher LD, Lokuta MA, Allen-Hoffmann BL,. Phase I/II clinical evaluation of StrataGraft: a consistent, pathogen-free human skin substitute. J Trauma 2009; 66: 866-873; discussion 73-4.
16. Thomas-Virnig CL, Centanni JM, Johnston CE, He LK, Schlosser SJ, Van Winkle KF, Chen R, Gibson AL, Szilagyi A, Li L, Shankar R, Allen-Hoffmann BL,. Inhibition of multidrug-resistant Acinetobacter baumannii by nonviral expression of hCAP-18 in a bioengineered human skin tissue. Mol Ther 2009; 17: 562-569.
17. Hoover DM, Wu Z, Tucker K, Lu W, Lubkowski J,. Antimicrobial characterization of human beta-defensin 3 derivatives. Antimicrob Agents Chemother 2003; 47: 2804-2809. (Pubitemid 37040251)
18. Stevenson JM, Gamelli RL, Shankar R,. A mouse model of burn wounding and sepsis. Methods Mol Med 2003; 78: 95-105.
19. Eckert RL, Crish JF, Robinson NA,. The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation. Physiol Rev 1997; 77: 397-424. (Pubitemid 27184344)
20. Supp DM, Karpinski AC, Boyce ST,. Expression of human beta-defensins HBD-1, HBD-2, and HBD-3 in cultured keratinocytes and skin substitutes. Burns 2004; 30: 643-648. (Pubitemid 39314508)
21. Pernet I, Reymermier C, Guezennec A, Branka JE, Guesnet J, Perrier E, Dezutter-Dambuyant C, Schmitt D, Viac J,. Calcium triggers beta-defensin (hBD-2 and hBD-3) and chemokine macrophage inflammatory protein-3 alpha (MIP-3alpha/CCL20) expression in monolayers of activated human keratinocytes. Exp Dermatol 2003; 12: 755-760. (Pubitemid 38028666)
22. Sawamura D, Goto M, Shibaki A, Akiyama M, McMillan JR, Abiko Y, Shimizu H,. Beta defensin-3 engineered epidermis shows highly protective effect for bacterial infection. Gene Ther 2005; 12: 857-861. (Pubitemid 40753978)
23. Straseski JA, Gibson AL, Thomas-Virnig CL, Allen-Hoffmann BA,. Oxygen deprivation inhibits basal keratinocyte proliferation in a model of human skin and induces regio-specific changes in the distribution of epidermal adherens junction proteins, aquaporin-3 and glycogen. Wound Rep Reg 2009; 17: 606-616.
24. Wickett RR, Nath V, Tanaka R, Hoath SB,. Use of continuous electrical capacitance and transepidermal water loss measurements for assessing barrier function in neonatal rat skin. Skin Pharmacol 1995; 8: 179-185.
25. Sorensen OE, Thapa DR, Roupe KM, Valore EV, Sjobring U, Roberts AA, Schmidtchen A, Ganz T,. Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J Clin Invest 2006; 116: 1878-1885. (Pubitemid 44033312)
26. Lehtinen J, Jarvinen S, Virta M, Lilius EM,. Real-time monitoring of antimicrobial activity with the multiparameter microplate assay. J Microbiol Methods 2006; 66: 381-389. (Pubitemid 44061989)
27. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H, Nieuwenhuizen WF, Jung G, Tarkowski A, van, Kessel KP, van, Strijp JA,. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001; 193: 1067-1076. (Pubitemid 32436200)
28. Braff MH, Zaiou M, Fierer J, Nizet V, Gallo RL,. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect Immun 2005; 73: 6771-6781. (Pubitemid 41368844)
29. Broughton G, 2nd, Janis JE, Attinger CE,. Wound healing: an overview. Plast Reconstr Surg 2006; 117 (Suppl.): 1e-S-32e-S. (Pubitemid 44334746)
30. Hancock RE, Sahl HG,. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-1557. (Pubitemid 44967479)
31. Zhang L, Falla TJ,. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother 2006; 7: 653-663.
32. Hengge UR,. Gene therapy progress and prospects: the skin-easily accessible, but still far away. Gene Ther 2006; 13: 1555-1563. (Pubitemid 44688456)
33. Scharschmidt T, Lo B,. Clinical trial design issues raised during recombinant DNA advisory committee review of gene transfer protocols. Hum Gene Ther 2006; 17: 448-454.
34. Carretero M, Del Rio M, Garcia M, Escamez MJ, Mirones I, Rivas L, Balague C, Jorcano JL, Larcher F,. A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides. FASEB J 2004; 18: 1931-1933. (Pubitemid 39602288)
35. Jacobsen F, Mittler D, Hirsch T, Gerhards A, Lehnhardt M, Voss B, Steinau HU, Steinstraesser L,. Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther 2005; 12: 1494-1502. (Pubitemid 41508674)
36. Lee PH, Ohtake T, Zaiou M, Murakami M, Rudisill JA, Lin KH, Gallo RL,. Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection. Proc Natl Acad Sci U S A 2005; 102: 3750-3755. (Pubitemid 40354683)
37. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, Tuckova L, Cukrowska B, Lodinova-Zadnikova R, Kozáková H, Rossmann P, Bá rtová J, Sokol D, Funda DP, Borovská D, Reháková Z, Sinkora J, Hofman J, Drastich P, Kokesová A,. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004; 93: 97-108. (Pubitemid 38678650)
38. Kisich KO, Howell MD, Boguniewicz M, Heizer HR, Watson NU, Leung DY,. The constitutive capacity of human keratinocytes to kill Staphylococcus. J Invest Dermatol 2007; 127: 2368-2380.
39. Steinstraesser L, Klein RD, Aminlari A, Fan MH, Khilanani V, Remick DG, Su GL, Wang SC,. Protegrin-1 enhances bacterial killing in thermally injured skin. Crit Care Med 2001; 29: 1431-1437. (Pubitemid 32641809)
40. Chen X, Niyonsaba F, Ushio H, Okuda D, Nagaoka I, Ikeda S, Okumura K, Ogawa H,. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci 2005; 40: 123-132. (Pubitemid 41446209)
41. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, Bonnart C, Descargues P, Hovnanian A, Gallo RL,. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006; 20: 2068-2080. (Pubitemid 44953906)
42. Bowler PG,. Wound pathophysiology, infection and therapeutic options. Ann Med 2002; 34: 419-427. (Pubitemid 36026773)
43. Hirsch T, Spielmann M, Zuhaili B, Fossum M, Metzig M, Koehler T, Steinau HU, Yao F, Onderdonk AB, Steinstraesser L, Eriksson E,. Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J Gene Med 2009; 11: 220-228.
44. Rasmussen CA, Gibson AL, Schlosser SJ, Schurr MJ, Allen-Hoffmann BL,. Chimeric composite skin substitutes for delivery of autologous keratinocytes to promote tissue regeneration. Ann Surg 2010; 251: 368-376.
45. McGuckin M, Goldman R, Bolton L, Salcido R,. The clinical relevance of microbiology in acute and chronic wounds. Adv Skin Wound Care 2003; 16: 12-23; quiz 4-5.